Table 5.

Treatment-emergent adverse events

10,000 IU QW (n = 39)20,000 IU Q2W (n = 76)20,000 IU Q4W (n = 72)40,000 IU Q4W (n = 72)
Adverse events in ≥10% of patients in any group, n (%)
    diarrhea4 (10.3)11 (14.5)6 (8.3)8 (11.1)
    constipation4 (10.3)1 (1.3)5 (6.9)1 (1.4)
    headache2 (5.1)3 (4.0)5 (6.9)8 (11.1)
Serious adverse events in ≥2  patients in any group, n (%)
    congestive cardiac failure3 (7.7)3 (4.0)1 (1.4)3 (4.2)
    diabetic ketoacidosis001 (1.4)2 (2.8)
  • QW, once weekly; Q2W, every 2 wk; Q4W, every 4 wk.